Timox contains Timolol, an antiglaucomatous, a reducer of intraocular pressure.
Pharmacokinetics and pharmacodynamics in humans
Timolol is a B1 and B2 (non-selective) adrenergic blocker, which reduces intraocular pressure by reducing the secretion of aqueous humor. The onset of action, after administration of a single dose of Timolol (Maleate), occurs in approximately 30 minutes. The maximum effect usually occurs 1 to 2 hours after application and a significant reduction in intraocular pressure up to 24 hours after a single dose.
Timox is indicated for the reduction of elevated intraocular pressure in patients with: Ocular hypertension, chronic open angle glaucoma, patients with aphakia and secondary glaucoma.
Timox is contraindicated in asthma (or a history of), chronic bronchitis, emphysema, or other lung diseases. Sinus bradycardia; second and third degree atrioventricular block, overt heart failure, and cardiogenic shock. Hypersensitivity to any component of the formula.
Each ml contains:
Timolol (Maleate) 5 mg
Excipients and purified water C.S.P. 1 ml
Posology and administration
Administration route: Ophthalmic.
A drop of Timox 0.5% instilled in the conjunctival sac every twelve hours or according to the doctor’s judgment.
Store at a temperature of 15 ° C and 25 ° C. Protect from freezing.
Box containing dropper bottle with 15 ml of solution.
Cautions and Warnings
Heart failure should be adequately controlled before starting timolol therapy. In patients with a history of severe heart disease, attention should be paid to the presence of signs of heart failure and the pulse rate should be checked.
Asthma (or a history of), bronchitis, emphysema, or other lung diseases: Serious breathing problems, including death due to bronchospasm, have been reported in patients with asthma after using timolol ophthalmic.
Diabetes mellitus (Diabetes saccharin): Timolol may mask some signs and symptoms of hypoglycemia, such as: fast heartbeat and tremor, but not dizziness or sweating.
Hyperactive thyroid: Timolol may mask certain signs and symptoms of hyperthyroidism. Stopping timolol abruptly can cause a sudden and dangerous increase in symptoms.
In angle-closure glaucoma, if Timolol is used, it must be accompanied by a miotic, since timolol has little effect on the dilation of the pupil.
Anaphylactic Reaction Risks: While taking beta blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to the sudden presence of such allergens, whether for accidental, diagnostic, or therapeutic reasons. . These types of patients may not respond to the usual doses of epinephrine used in the treatment of anaphylactic reactions.
Precautions or restrictions on use during pregnancy and lactation
Pregnancy: The body can absorb timolol ophthalmic. No human studies on birth defects have been performed.
Lactation: Timolol ophthalmic can be absorbed into the body and pass into breast milk, which may cause undesired effects in the infant, the decision should be made to discontinue breastfeeding or to discontinue the medication taking into account its importance for the mother.
Pediatric use: Safety and efficacy in pediatric patients have not been established.
Occasionally it can produce burning, tearing, blurred vision or headache, which disappear quickly.
Eye irritation or inflammation, skin rash, hives or itching, vision disturbance. These reactions require medical attention.
If significant systemic absorption of Timolol occurs, it produces: anxiety, chest pain, confusion or mental depression, decreased sexual ability, diarrhea, dizziness or fainting, hallucinations, headache, irregular, slow heartbeat, or palpitations , nausea or vomiting, stomach cramps or pain, swelling of the feet, ankles and / or lower legs, unusual tiredness or weakness, wheezing or trouble breathing.
There is potentially a potential for additive effects capable of causing systemic hypotension and / or pronounced bradycardia when timolol maleate ophthalmic solution is administered concomitantly with calcium channel blockers, catecholamine depressant drugs or beta-blockers, antiarrhythmics (including amiodarone and quinidine), digitalis glycosides, parasympathomimetics, narcotics and monoamine oxidase inhibitors (MAO). The effect on intraocular pressure or the known effects of systemic beta blocking may be potentiated when timolol maleate is administered to patients who have already received an oral beta adrenergic blocking agent, therefore the use of two or more beta blocking agents is not recommended. topical adrenergics. Oral hypoglycemic drugs and insulin can increase the risk of hyperglycemia or hypoglycemia.